Stay updated on Pembrolizumab + Nab-Paclitaxel in NSCLC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab + Nab-Paclitaxel in NSCLC Clinical Trial page.

Latest updates to the Pembrolizumab + Nab-Paclitaxel in NSCLC Clinical Trial page
- Check3 days agoChange DetectedThe page revision label changed from v3.6.2 to v3.6.3, indicating a minor update to the page version. This update does not change the displayed study information and is likely a backend tweak or small fix.SummaryDifference0.1%

- Check10 days agoChange DetectedAdds a new site revision label 'Revision: v3.6.2' to the page and removes several related topic tags ('Lung cancer', 'related topics:', 'MedlinePlus Genetics') as well as the earlier 'Revision: v3.6.0' tag. This update appears to streamline the page's metadata and navigation by updating the revision reference and pruning older or less relevant topics.SummaryDifference0.3%

- Check17 days agoChange DetectedAdded related topics links for Lung cancer and MedlinePlus Genetics to the page; these expand available health-information resources without altering study details.SummaryDifference0.2%

- Check24 days agoChange DetectedThe recruitment status is updated to closed, and new guidance links were added to help users read the study record and join a study. Minor UI/content updates include a header label adjustment (Intervention/Treatment), a revision tag, and removal of some related-topic terms.SummaryDifference0.6%

- Check31 days agoChange DetectedThe page revision label was updated from v3.5.4 to v3.5.5, indicating a minor metadata update. No study data or visible content appears to be affected.SummaryDifference0.1%

- Check38 days agoChange DetectedThe related topics header and its entries (Lung cancer and MedlinePlus Genetics) were removed, reducing quick links to disease-related resources on the page.SummaryDifference0.2%

Stay in the know with updates to Pembrolizumab + Nab-Paclitaxel in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab + Nab-Paclitaxel in NSCLC Clinical Trial page.